A clinical trial should never accrue a patient when the data collected to date indicate that this accrual could be unethical. An interim monitoring plan is a crude tool written into protocols to provide this assurance. At the University of Pittsburgh Cancer Institute, we have designed a software architecture to automate interim monitoring, acting appropriately when information required to determine whether a stopping criterion is fulfilled is missing. The design is modular and flexible.